Brokers Offer Predictions for Antibe Therapeutics Inc.’s FY2024 Earnings (OTCMKTS:ATBPF)

Antibe Therapeutics Inc. (OTCMKTS:ATBPFFree Report) – Equities researchers at Echelon Wealth Partners boosted their FY2024 earnings per share (EPS) estimates for shares of Antibe Therapeutics in a report released on Monday, November 13th. Echelon Wealth Partners analyst S. Quenneville now anticipates that the company will post earnings of ($0.32) per share for the year, up from their previous forecast of ($0.35). The consensus estimate for Antibe Therapeutics’ current full-year earnings is ($0.31) per share.

Separately, Brookline Capital Management restated a “buy” rating on shares of Antibe Therapeutics in a report on Monday, August 14th.

Check Out Our Latest Stock Report on Antibe Therapeutics

Antibe Therapeutics Stock Performance

ATBPF opened at $0.55 on Thursday. Antibe Therapeutics has a 1 year low of $0.28 and a 1 year high of $0.89. The company’s 50 day simple moving average is $0.44 and its 200 day simple moving average is $0.40. The stock has a market capitalization of $28.90 million, a PE ratio of -2.20 and a beta of 0.27.

Antibe Therapeutics (OTCMKTS:ATBPFGet Free Report) last issued its quarterly earnings results on Monday, November 13th. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.02.

Antibe Therapeutics Company Profile

(Get Free Report)

Antibe Therapeutics Inc, a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs).

Read More

Earnings History and Estimates for Antibe Therapeutics (OTCMKTS:ATBPF)

Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with's FREE daily email newsletter.